Sublingual immunotherapy with allergenic extract of Dermatophagoides pteronyssinus in asthmatic children;Inmunoterapia sublingual con extracto alergénico de Dermatophagoides pteronyssinus en niños con asma

Revista Alergia Mexico

Volumn 51, Issue 5, 2004, Pages 177-180

  Santos, Olimpio Rodríguez ^a,b,c  

^a UNIVERSIDAD DE CAMAGÜEY   (Cuba)

^b Sociedad Iberoamericana de Información Científica   (Cuba)

^c Edificio D Apartamento 2 E Bembeta y Lugareno Reparto Boves   (Cuba)

Author keywords

Allergy; Asthma; Dermatophagoides pteronyssinus; Sublingual immunotherapy

Indexed keywords

BRONCHODILATING AGENT; HOUSE DUST ALLERGEN; IMMUNOGLOBULIN E; STEROID; ANTIASTHMATIC AGENT; CORTICOSTEROID; TISSUE EXTRACT;

ADOLESCENT; ALLERGY; ARTICLE; ASTHMA; CHILD; CLINICAL ARTICLE; CONFIDENCE INTERVAL; CONTROLLED STUDY; DERMATOPHAGOIDES PTERONYSSINUS; DRUG EFFICACY; FEMALE; HUMAN; IMMUNOTHERAPY; MALE; PEAK EXPIRATORY FLOW; RISK FACTOR; SPIROMETRY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DESENSITIZATION; DOSE RESPONSE; IMMUNOLOGY; MULTIMODALITY CANCER THERAPY; PATHOPHYSIOLOGY; PYROGLYPHIDAE; RANDOMIZED CONTROLLED TRIAL; SUBLINGUAL DRUG ADMINISTRATION; TREATMENT OUTCOME;

ADMINISTRATION, SUBLINGUAL; ADOLESCENT; ADRENAL CORTEX HORMONES; ANTI-ASTHMATIC AGENTS; ANTIGENS, DERMATOPHAGOIDES; ASTHMA; CHILD; COMBINED MODALITY THERAPY; DESENSITIZATION, IMMUNOLOGIC; DOSE-RESPONSE RELATIONSHIP, IMMUNOLOGIC; FEMALE; HUMANS; MALE; PEAK EXPIRATORY FLOW RATE; PYROGLYPHIDAE; TISSUE EXTRACTS; TREATMENT OUTCOME;

EID: 17844378487     PISSN: 00025151     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (20)

1. Frati F, Sensi L, Di Rienzo V, Senna GE, Incorvaia C, Marcucci F. A model for management of sublingual immunotherapy. Allerg Immunol (Paris) 2003;35(2):56-60.
2. Canonica GW, Passalacqua G. Non-injection routes for immunotherapy. J Allergy Clin Immunol 2003;111(3):437-48.
3. Madonini E, Agostinis F, Barra R, Berra A, Donadio D, Pappacoda A, et al. Long-term and preventive effects of sublingual allergen-specific immunotherapy: a retrospective, multicentric study. Int J Immunopathol Pharmacol 2003;16(1):73-79.
4. Schmidt-Weber CB, Blaser KT. T-cell tolerance in allergic response. Allergy 2002;(57):762-8.
5. Di Rienzo V, Marcucci F, Puccinelli P, Parmiani S, Frati F, Sensi L, et al. Long-lasting effect of sublingual immunotherapy in children with asthma due to house dust mite: a 10-year prospective study. Clin Exp Allergy 2003;33(2):206-10.
6. Silvestri M, Spallarossa D, Battistini E, Sabatini F, Pecora S, Parmiani S, et al. Changes in inflammatory and clinical parameters and in bronchial hyperreactivity asthmatic children sensitized to house dust mites following sublingual immunotherapy. J Investig Allergol Clin Immunol 2002;12(1):52-59.
7. Tari MG, Mancino M, Monti G. Efficacy of sublingual immunotherapy in patients with rhinitis and asthma due to house dust mite. A double-blind study. Allergol Immunopathol (Madr) 1990;18(5):277-84.
8. Passalacqua G, Canonica GW. Allergen-specific sublingual immunotherapy for respiratory allergy. BioDrugs 2001;15(8):509-19.
9. Bahççeciler NN, Isik U, Barlan IB, Basaran MM. Efficacy of sublingual immunotherapy in children with asthma and rhinitis: a double-blind, placebo-controlled study. Pediatr Pulmonol 2001;32(1):49-55.
10. Frew AJ, Smith HE. Sublingual immunotherapy. J Allergy Clin Immunol 2001;107(3):441-4.
11. Pajno GB, Morabito L, Barberio G, Parmiani S. Clinical and immunologic effects of long-term sublingual immunotherapy in asthmatic children sensitized to mites: a double-blind, placebo-controlled study. Allergy 2000;55(9):842-9.
12. Guez S, Vatrinet C, Fadel R, André C. House-dust-mite sublingual-swallow immunotherapy (SLIT) in perennial rhinitis: a double-blind, placebo-controlled study. Allergy 2000;55(4):369-75.
13. André C, Vatrinet C, Galvain S, Carat F, Sicard H. Safety of sublingual-swallow immunotherapy in children and adults. Int Arch Allergy Immunol 2000;121(3):229-34.
14. Mungan D, Misirligil Z, Gürbüz L. Comparison of the efficacy of subcutaneous and sublingual immunotherapy in mite-sensitive patients with rhinitis and asthma: a placebo controlled study. Ann Allergy Asthma Immunol 1999;82(5):485-90.
15. Bousquet J, Scheinmann P, Guinnepain MT, Perrin-Fayolle M, Sauvaget J, Tonnel AB, et al. Sublingual-swallow immunotherapy (SLIT) in patients with asthma due to house-dust mites: a double-blind, placebo-controlled study. Allergy 1999;54(3):249-60.
16. Passalacqua G, Albano M, Fregonese L, Riccio A, Pronzato C, Mela GS, et al. Randomized controlled trial of local allergoid immunotherapy on allergic inflammation in mite-induced rhinoconjunctivitis. Lancet 1998;351(9103):629-32.
17. Hirsch T, Sähn M, Leupold W. Double-blind placebo-controlled study of sublingual immunotherapy with house dust mite extract (D.pt.) in children. Pediatr Allergy Immunol 1997;8(1):21-27.
18. Almagro E, Asensio O, Bartolomé JM, Bosque M, de la Hoz B, Dolz I, et al. Estudio multicéntrico de farmacovigilancia de inmunoterapia sublingual en pacientes alérgicos. Allergol Immunopathol (Madr) 1995;23(4):153-9.
19. Tari MG, Mancino M, Madonna F, Buzzoni L, Parmiani S. Immunologic evaluation of 24 month course of sublingual immunotherapy. Allergol Immunopathol (Madr) 1994;22(5):209-16.
20. Wilson DR, Torres Lima M, Durham SR. Sublingual immunotherapy for allergic rhinitis (Cochrane Review). In: The Cochrane Library. Oxford: Update Software, 2003.